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The  major  histocompatibility complex  (MHC)  in the  mouse  strongly  influences 
allograft rejection. This complex can be divided into four regions separable by genetic 
recombination (1, 2). Two regions, H-2K and H-2D,  at the left and right ends of the 
complex, respectively, contain loci controlling serologically detectable (SD)  antigens. 
An immune response  (/r)  region,  next  to  H-2K,  includes genetic loci  determining 
immune responsiveness (3, 4) ; between Ir and H-2D is a fourth region marked by the 
Ss-Slp locus (5). 
Two in vitro tests can be used to detect differences at the MHC between different 
inbred mouse strains. Mixed lymphocyte cultures  (MLC)  measure  the proliferative 
response of lymphocytes of one strain as they react to histocompatibility differences 
of a  second strain (6). Responding cells activated in MLC  to allogeneic MHC  anti- 
gens can lyse 51Cr-labeled  target lymphocytes in the cell-mediated lympholysis (CML) 
assay  (7).  Recent studies suggest that MHC  differences that have not been defined 
serologically are  primarily responsible for  lymphocyte  activation in MLC  (8).  We 
have  called such differences  "lymphocyte defined"  (LD)  to contrast them with  the 
SD differences associated with the H-2K and H-2D regions. The LD differences pri- 
marily map between H-2K and H-2D. Lymphocyte-defined differences of the MHC 
probably also  exist in man  (9-12).  Recently Eijsvoogel et  al.  demonstrated  in one 
family in man that these presumed LD  differences, which lead to MLC  activation, 
were not sufficient to serve as a  "target"  in CML; thus for significant CML to occur 
it was necessary to include the SD differences on the target cells. Further, only one of 
* Supported  by National Institutes of Health  grants GM-18314,  DE-02731,  AI-08439, 
GM-15422,  and  AI-06525;  National Foundation-March of  Dimes  grant  CRBS  246;  and 
Office of Naval Research grant N000-67-A-128-0003. This is paper no. 1,619 from the Labora- 
tory of Genetics, University of Wisconsin, Madison, Wis. 53706. 
:~ D.J.S. is an NIH Trainee supported by National Institute of General Medical Sciences 
grant GM-00398. 
§ M.L.B. is a recipient of the American Cancer Society Faculty Research Award. 
THE JOURNAL OF EXPERIMENTAL MEDICINE  -  VOLUME 137,  1973  1303 1304  ALTER  ET  AL.  BRIEF  DEFINITIVE  REPORT 
the SD loci of ttL-A  (the Four locus region)  appeared  to serve as a  target for CML 
(13).  The need for SD  differences for  CML  was likewise suggested by the studies of 
Trinchieri et al.  (14). 
Our  present  studies  in  mouse  further  investigate  the  role  of  LD  and  SD 
differences  in CML.  In  certain  strain  combinations  that  are SD  identical  but 
different  for  LD  (i.e.  there  is  MLC  reactivity)  there  is  no  CML.  However, 
the presence  of  either  an H-2K  or  an H-2D  region  difference  (thus including 
an SD  difference)  is sufficient for significant CML  to occur. 
Materials and Methods 
Mice used in these studies are raised in our own colonies. These strains differ for various 
regions of the MHC and have been discussed in detail (8). All strains used, except AQR, 1 are 
congenic, i.e., they are genetically identical except for differences in the MHC. However the 
effects seen with AQR in MLC seem attributable to the MIIC (8). We refer to the four regions 
on the NIHC  chromosome  (H-2K,  lr,  Ss,  and H-2D  from left  to right)  with four  capital 
letters, one for each of the four regions. For instance, strain B10.A, which carries the H-2 a 
chromosome, is designated KKDD; it has the H-2K and Ir regions derived from an H-2  ~ 
chromosome, and the Ss and H-2D regions derived from an 1t-2  d chromosome.  (Lower case 
superscripts refer to the different H-2 chromosomes; capital letters, which are not written as 
superscripts,  to  the various  regions.)  Strain BI0.A(2R)  is derived from an H-2~/H-2  ~  het- 
erozygous  animal  after  a  recombinational event  between  Ss  and  H-2D.  The  B10.A(2R) 
(KKDB)  animal has the H-2K, Ir, and Ss regions derived from the H-2  '~ chromosome, and 
the H-ZD region derived from the H-2  ~ chromosome. B10.A and B10.A(2R)  thus differ only 
for H-2D;  B10 and B10.A(2R)  differ for tt-2K,  It,  and Ss but are identical for H-2D.  In 
some cases, since the chromosomes in question are derived from the same heterozygous geno- 
type,  we  can  be certain that  two regions carrying the same designations are identical; in 
other cases we cannot be sure of identity by genetic derivation and rely on phenotypic identity, 
for serological factors for instance. 
MLC tests are done using the micromethod of Widmer et al.  (15).  All cells are cultured in 
RPMI  1640  (Grand Island Biological Company,  Grand Island, N.  Y.),  supplemented with 
penicillin,  streptomycin,  and  5%  heat-inactivated  human  plasma.  Stimulating  cells  are 
treated with mitomycin C. Cultures used for assay of 3/ILC  reactivity are labeled with triti- 
ated thym;dine for 16-18 h 3 days after initiation of culture. 
Effecto,-  cells,  to be used in CML,  are obtained from MLC after 88-90 h  of incubation. 
These cells are suspended at 1 X  107 viable cells/ml in RPMI 1640 with 5% heat-inactivated 
fetal calf serum. 
Target cells for CML are prepared from lymph nodes and incubated in RPMI 1640 with 
5% fetal calf serum. 3 days before use they are stimulated with phytohemagglutinin. The ceils 
are  labeled with 250  ~Ci of Na~[51Cr]O4 (New England Nuclear,  Boston,  Mass.)  at  37°C 
in 5% CO2 for 60 rain. After three washes they are adjusted to a  concentration  of 1 X  105 
viable cells/ml in RPNII 1640 with 5% heat-inactivated fetal calf serum. 
For the CML assay, 0.75 X  106 to 1 X  106 effector cells are incubated with 1 X  104 target 
cells in Linbro round-bottom microtiter plates (no. IS-MRC-96TC).  After 3 h  of incubation 
at 37°C, 0.05 ml of 5% fetal calf serum in RPMI 1640 is added to each well and the cells are 
centrifuged in the plates. A constant aliquot of the supernatant fluid is aspirated from each 
well and the amount of radioactivity released in the supernatant fluid determined. The maxi- 
mum  release  (MR)  value  of  each  target cell preparation is measured  by determining the 
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amount  of  SXCr released into  the supernatant fluid  by  1  X  104  cells  after repeated freeze- 
thawing. Spontaneous release (SR)  of 51Cr from the same number of target cells, incubated in 
medium alone for 3  h, is also measured. Quantitation of the test is expressed as percent (% 
51Cr release) of  (net experimental release [ER]  --  spontaneous release [SR])  divided by (net 
total  release  [MR]  --  [SR]),  as  given by the formula (ER  --  SR/MR  --  SR)  X  100. All 
assays are done in triplicate. 
RESULTS  AND  DISCUSSION 
The two strain combinations [AQR-B10.T(6R)  and B10.A(4R)-B10.A(2R)] 
of greatest interest in these studies have LD differences associated with MLC 
TABLE I 
MLC and  CML with SD-Identlcal,  LD-Different  Combinations 
MLC sensitization  CML assay 
Responding  cell  Stimulating cell  5tCr 
MLC  (effector)  (sensitizing)  Target cell  released  CML 
mean cpm 4- SD  mean cpm ~  SD  % 
A*  45,841 4-  1,921  AQR (QKDD)~.  B10.T(6R)  (QQQD)  AQR (QKDD)  489 4-  51  --5.1 
B10.T(6R)  (QQQD)  558  4- 50  2.2 
63,491 4- 4,511  B10.T(6R)  (QQQD)  AQR (QKDD)  B10.T(6R)  (QQQD)  471 4-  7  5.0 
AQR (QKDD)  475 4-  23  --6.0 
49,763 q-  1,726  AQR (QKDD)  C57BL/10 (BBBB)  AQR (QKDD)  690 4- 41  9.5 
C57BL/10 (BBBB)  1,158 4-  66  66.9 
70,687 4- 3,425  B10.T(6R)  (QQQD)  B10.A(2R)  (KKDB)  B10.T(6R)  (QQQD)  716 4-  18  15.3 
B10.A(2R)  (KKDB)  2,004 4- 58  74.5 
64,048 4-  1,846  C57BL/10 (BBBB)  AQR (QKDD)  C57BL/10 (BBBB)  709 4-  20  7.3 
AQR (QKDD)  1,749 4-  114  86.5 
52,782 q-  1,534  C57BL/10 (BBBB)  BI0.T(6R) (QQQD)  C57BL/10 (BBBB)  706 4-  6  7.0 
B10.T(6R)  (QQQD)  1,565  4-  151  85.4 
12,327 4-  1,901  AQR (QKDD)  AQR (QKDD)  AQR (QKDD)  436 4- 31  8.9 
15,101 4-  529  B10.T(6R)  (QQQD)  B10.T(6R)  (QQQD)  B10.T(6R)  (QQQD)  488 4- 35  --3.6 
14,843 4- 3,858  C57BL/10 (BBBB)  C57BL/10 (BBBB)  C57BL/10 (BBBB)  438 4-  14  --28,5 
B§  18,729 4- 3,810  B10.A(4R)  (KKBB)  B10.A(2R)  (KKDB)  B10.A(4R)  (KKBB)  468 4-  25  --4.6 
B10.A(2R)  (KKDB)  469 -4- 8  --5.5 
98,911 4-  2,753  BI0.A(4R) (KKBB)  C57BL/10 (BBBB)  I~10.A(4R)  (KKBB)  747  4-  62  27.0 
C57BL/10  (BBBB)  1,345 4- 30  74.1 
44,163 ±  5,606  C57BL/10 (BBBB)  B10.A(2R)  (KKDB)  C57BL/10 (BBBB)  697  4-  38  3.8 
Bt0.A(2R)  (KKDB)  1,184  ~  17  62.2 
6,430 4-  2,204  B10.A(4R)  (KKBB)  B10.A(4R)  (KKBB)  B10.A(4R)  (KKBB)  437  4- 52  --8.2 
18,057 4-  2,815  C57BL/10 (BBBB)  C57BL/10 (BBBB)  C57BL/10 (BBBB)  578  4-  45  --9.1 
* The percent CML is based on the following spontaneous release (SR) and maximum release  (MR) values (mean of 
triplicates ±  SD) for each target cell: AQR, SR =  558 4- 6  MR =  1,935 q- 53;  B10.T(6R),  SR ~  531-4- 35  MR 
=  1,742 4- 94;  C57BL/10, SR  =  653 ~: 56  MR =  1,408 4- 81;  B10.A(2R),  SR =  621 4- 77  MR =  2,476 4- 179. 
:~ The four capital letters (i.e., QKDD) refer to the various regions of the MHC as explained in the text. 
§ The percent CML is based on the following spontaneous  release  (SR) and maximum release  (MR) values (mean 4- 
SD of triplicates) for each target cell:  B10.A(4R),  SR =  809 4- 42  MR =  1,388 :h 116; BI0.A(2R), SR =  527 4- 29 
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activation  (8)  and  graft-vs.-host  reactions,-"  but  are  SD  identical.  Table  I 
shows  the  results  of  MLC  and  CML  tests  in  these  combinations.  Despite 
significant MLC activation, AQR effector cells do not lyse  B10.T(6R)  target 
cells nor do B10.T(6R)  effector cells lyse AQR  target  cells.  Both  AQR  and 
B10.T(6R)  cells  are  capable of mediating  CML  when  sensitized  and  tested 
against  target cells that differ in  several regions of the  MHC;  likewise these 
cells are extensively lysed when used as target cells in  combinations differing 
TABLE  II 
3/[LC  and  CML  with  SD-Different  Combinations 
MLC sensitization  CML assay 
Responding cell  Stimulating cell 
MLC  (effector)  (sensitizing)  Target cell  ~lCr  released  CML 
mean cpm 4. SD  mean cpm ~  SD  % 
A*  14,819  ::h 1,406  B10.A (KKDD)  AQR (QKDD)  B10.A  (KKDD)  469  9=  11  --4.6 
AQR (QKDD)  372  =h  36  --3.6 
44,777  ±  5,237  BI0.A (KKDD)  B10.T(6R)  (QQQD)  B10,A (KKDD)  484  4.  21  --1.4 
B10,T(6R)  (QQQD)  534  4.  19  37.5 
AQR (QKDD)  623  --  19  42.6 
C57BL/10 (BBBB)  383  zh  33  13.8 
14,487  4.  846  B10.A (KKDD)  B10.A  (KKDD)  B10.A (KKDD)  417  =h  54  --15.4 
B~;  13,725  =h  2,236  B10.A(2R)  (KKDB)  BI0.A (KKDD)  BI0.A(2R) (KKDB)  532  4-  142  --4.9 
B10.A (KKDD)  552  ~  13  5.3 
79,236  =[=  6,902  B10.A(2R)  (KKDB)  B10.D2  (DDDD)  B10.A(2R)  (KKDB)  889  =h  67  24.9 
B10.D2 (DDDD)  1,541  =h  140  72.3 
BI0.A (KKDD)  1,041  4-  32  78.5 
C57BL/lO (BBBB)  1,232  4.  43  40.6 
10,423  z~  623  B10.A(2R)  (KKDB)  B10.A(2R)  (KKDB)  B10.A(2R)  (KKDB)  434  4.  7  --13.1 
The percent CML is based on the following spontaneous  release  (SR)  and  maximum release  (MR)  values (mean of 
triplicates ::l: SD)  for each target cell. 
* B10.A,  SR  =  49I  4- 20  MR  ~  974 :h 61;  AQR,  SR  =  391 4-  24  MR  =  935 :i: 45;  B10T(6R),  SR =  328 :i: 
25  MR  =  877 =[=  66;  C57BL/10, SR  =  323 =h 19  MR  -  749 :t- 22. 
.+ B10.A(2R),  SR  =  591 =h 23  MR ~  1,786 zh 60,  B10.A,  SR =  316 4-  14  MR  =  1,184 :t= 59;  B10.D2,  SR 
684 4- 47  MR  =  1,869 4. 34;  C57SL/10, SR =  721 4- 73  MR =  1,978 4. 30. 
in all four regions of the MHC.  Similar results are obtained when  B10.A(4R) 
cells are tested in combination with B10.A(2R)  cells. Despite  MLC  activation 
there is no CML. 
Table  II  shows  the  results  of  experiments  testing  whether  differences  at 
either end of the MHC can lead to CML. In the first combination (B 10.A  AQR) 
the  effector and  target cells differ for the tt-2K region,  but  are identical for 
the It, Ss,  and H-2D regions. There  is  no MLC activation nor CML  in  this 
combination.  However, when  B10.A  is  sensitized  against  B10.T(6R),  which 
differs for the H-2K, Ir, and Ss regions, one finds strong MLC activation and 
significant CML directed at the B10.T(6R)  target cell.  These  B10.A  effector 
Livnat,  S., J.  Klein, and  F.  H.  Bach.  1973.  Graft  versus host reaction in strains of mice 
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cells are also cytotoxic to AQR target cells. Therefore, if the effector cells are 
properly activated the H-2K region difference alone is a  sufficient  target  for 
CML. 
Similarly,  when  one  sensitizes  the  effector cell population  against  only an 
H-2D  region  difference [B10.A(2R)-B10.Am],  there  is  neither  MLC  activa- 
tion  nor  CML  (Table II B).  The  B10.A(2R)-B10.D2  combination  leads  to 
strong MLC activation and CML; CML occurs also on the B10.A  target cells, 
which differ from the B10.A(2R)  effector cells at only the  H-2D  region.  Less 
CML  occurs  if  the  effector  cell  is  confronted  with  a  target  cell  carrying  a 
different H-2K or H-2D region. 
Our present studies confirm the observation in man that in some instances 
an LD  difference  is  sufficient  to  give  MLC  activation  but  not  sufficient  to 
allow  CML.  Those  combinations  with  SD  differences  and  MLC  activations 
lead to CML whether the SD differences are associated with the H-2K region 
or the H-2D region. This contrasts with the findings in man where differences 
at one of the two SD loci appear to play the predominant role in CML (13). 
Whether  it  is  the  serologically  defined  antigens  themselves  that  are  the 
targets for CML must be left open for further investigation.  We have noted 
that  significant  CML occurs in the  C57BL/6-H(zl)  combination  (16).  These 
strains differ by a spontaneous mutation in the MHC, which leads to reciprocal 
MLC  activation,  skin graft rejection,  and  CML. Although  it is possible that 
C57BL/6  and  H(zl)  differ by antigens  that  can be defined  serologically, no 
such differences have been detected to date (17). 
There are at least two models that can explain the apparent dichotomy be- 
tween  the lack of  CML  in  the  AQR-B10.T(6R)  and  B10.A(4R)-B10.A(2R) 
combinations and significant CML in C57BL/6-H(zl). The first model is that 
SD  differences  are  in  fact  the  targets  for  CML;  C57BL/6  and  H(zl)  may 
actually differ serologically. If such an SD  difference exists, it is not detected 
as  measured  by  antibody  production  after  cross-immunization  between  the 
two  strains  but  is recognized  in  CML  after MLC  between  the  two  strains. 
This could reflect the greater ease with which the same antigen triggers T cells in 
MLC compared with triggering of B cells for antibody production; alternatively 
it could indicate a qualitative  difference, e.g., that  the T  cells recognize differ- 
ences that B  cells cannot recognize. The second model hypothesizes that there 
are two types of LD differences. One type controls the "activation" of cellular 
"proliferation" as measured in MLC; the second determines the target mole- 
cules detected in CML. The "LD target" differences are determined by genes 
closely linked  to those determining the  SD  antigens. The mutation in H(zl) 
could have affected both  MLC  and  CML.  The AQR-B10.T(6R)  and  B10.A- 
(4R)-B10.A(2R)  combination would not have an LD  target  difference. It will 
require further experimentation to determine whether the SD  antigens are in 
most  cases  acting  as  markers  to  linked  LD  target  loci  or  are  themselves a 
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An  intriguing  possibility is  that  the  complexity of the  genetic  control  for 
these reactions (the existence of either more than one type of LD locus or the 
dual  control  by  an  LD-activating  locus  and  an  SD  target  locus)  might  be 
paralleled by a  dual  cell system involved in  the reactions.  One population of 
lymphocytes would  recognize  "LD-activating"  differences of the  MHC.  The 
proliferation of these cells may be a  necessary event allowing the subsequent 
activation of a  second population that would recognize either the SD antigens 
or the phenotypic product of a closely linked LD target locus (18). 
Note Added in Proof.--We have recently demonstrated two separate cell  popula- 
tions' response in MLC and CML reactions [Bach,  F. H., M. Segall,  K. S. Zier,  P. 
M.  Sondel, B. J. Alter, and M. L. Bach.  1973. Cell mediated immunity:  separation 
of cells involved in recognltive and destructive phases. Science (Wash. D.C.). In press.]. 
In addition, we have shown that if a given responding cell is stimulated by two differ- 
ent  cell populations,  one  differing  from the  responding  cell by LD  and  the  other 
differing from the responding cell by SD,  the responding  cell will subsequently be 
cytotoxic in CML against the target cell carrying the SD antigens (Schendel,  D. J., 
unpublished observations). 
SUMMARY 
The  cell-mediated  lympholytic capability of mouse  spleen  cells stimulated 
in  mixed lymphocyte culture  is related  to the major histocompatibility com- 
plex  genotype  on  target  lymphocytes.  The  strain  combinations  AQR-B10. 
T(6R) and B10.A(4R)-B 10.A(2R)  that result in significant mixed lymphocyte 
culture  activation  do  not  mediate  cell-mediated  lympholysis  on  sensitizing 
target lymphocytes; serologically defined regions (H-2K and H-2D)  are iden- 
tical within each combination. H-dK  or H-2D region disparity alone does not 
cause cell-mediated lympholysis. However after mixed lymphocyte culture acti- 
vation  as seen with  B10.A-B10.T(6R),  a  target  cell  bearing  only  an  //-2K 
region  difference  from  the  effector cell  is  sensitive to cell-mediated  lymph- 
olysis. Likewise an II-2D region difference is an adequate  target after mixed 
lymphocyte  culture  activation  of  the  effector  cell  in  the  combination 
B10.A(2R)-B10.D2. 
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